FAKTOR OPTIONSSCHEIN - BIOGEN IDEC | Market Closed - Börse Stuttgart 20:58:09 23/05/2024 BST | ||
| 3.74 EUR | +34.05% |
|
| Current month | -32.25% | ||
| 1 month | -82.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 3.74 | +34.05% |
| 22/05/24 | 2.79 | +8.56% |
| 21/05/24 | 2.57 | +13.72% |
| 20/05/24 | 2.26 | -6.61% |
| 17/05/24 | 2.42 | +1.26% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 08:58 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD462X |
| ISIN | DE000HD462X3 |
| Date issued | 27/03/2024 |
| Strike | 247.7 $ |
| Maturity | Unlimited |
| Parity | 8.71 : 1 |
| Emission price | 9.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.49 € |
|---|---|
| Lowest since issue | 1.82 € |
| Spread | 0.23 € |
| Spread % | 5.81% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
218.1
USD
Average target price
287.3
USD
Spread / Average Target
+31.75%
- Stock Market
- Certificates
- Certificat
